Stock Track | BridgeBio Pharma Plummets 5.06% as Trial Data Disappoints

Stock Track

Nov 19, 2024

BridgeBio Pharma, Inc. (BBIO) stock plummeted 5.06% in the intraday trading on Monday, as the biopharmaceutical company disclosed mixed trial results for its investigational therapies.

The company announced the publication of 18-month results from PROPEL 2, a Phase 2 trial of its investigational therapy infigratinib in children with achondroplasia, a form of dwarfism. While the therapy showed some positive effects, the results were not as promising as investors had hoped, leading to disappointment in the market.

Additionally, BridgeBio presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM (transthyretin amyloid cardiomyopathy) at the American Heart Association Scientific Sessions. The data, while encouraging, failed to significantly boost investor confidence in the therapy's potential.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1180713247"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1180713247\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1180713247?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-19 04:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1180713247","market":"hk","top_or_hot":-1,"title":"Stock Track | BridgeBio Pharma Plummets 5.06% as Trial Data Disappoints","media":"Stock Track","content":"<p>BridgeBio Pharma, Inc. (BBIO) stock plummeted 5.06% in the intraday trading on Monday, as the biopharmaceutical company disclosed mixed trial results for its investigational therapies.</p>\n\n<p>The company announced the publication of 18-month results from PROPEL 2, a Phase 2 trial of its investigational therapy infigratinib in children with achondroplasia, a form of dwarfism. While the therapy showed some positive effects, the results were not as promising as investors had hoped, leading to disappointment in the market.</p>\n\n<p>Additionally, BridgeBio presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM (transthyretin amyloid cardiomyopathy) at the American Heart Association Scientific Sessions. The data, while encouraging, failed to significantly boost investor confidence in the therapy's potential.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BridgeBio Pharma Plummets 5.06% as Trial Data Disappoints</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BridgeBio Pharma Plummets 5.06% as Trial Data Disappoints\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-19 04:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BridgeBio Pharma, Inc. (BBIO) stock plummeted 5.06% in the intraday trading on Monday, as the biopharmaceutical company disclosed mixed trial results for its investigational therapies.</p>\n\n<p>The company announced the publication of 18-month results from PROPEL 2, a Phase 2 trial of its investigational therapy infigratinib in children with achondroplasia, a form of dwarfism. While the therapy showed some positive effects, the results were not as promising as investors had hoped, leading to disappointment in the market.</p>\n\n<p>Additionally, BridgeBio presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM (transthyretin amyloid cardiomyopathy) at the American Heart Association Scientific Sessions. The data, while encouraging, failed to significantly boost investor confidence in the therapy's potential.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BBIO","symbol_name":"BridgeBio Pharma, Inc.","start_time":0,"source_url":"","article_id":"1180713247","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1180713247","pubTimestamp":1731961102,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BridgeBio Pharma, Inc.  stock plummeted 5.06% in the intraday trading on Monday, as the biopharmaceutical company disclosed mixed trial results for its investigational therapies.The company announced the publication of 18-month results from PROPEL 2, a Phase 2 trial of its investigational therapy infigratinib in children with achondroplasia, a form of dwarfism. While the therapy showed some positive effects, the results were not as promising as investors had hoped, leading to disappointment in t","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BBIO":"BridgeBio Pharma, Inc."},"translate_title":"由于试验数据令人失望，股票轨迹BridgeBio Pharma暴跌5.06%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BBIO":1},"content_text":"BridgeBio Pharma, Inc. (BBIO) stock plummeted 5.06% in the intraday trading on Monday, as the biopharmaceutical company disclosed mixed trial results for its investigational therapies.\nThe company announced the publication of 18-month results from PROPEL 2, a Phase 2 trial of its investigational therapy infigratinib in children with achondroplasia, a form of dwarfism. While the therapy showed some positive effects, the results were not as promising as investors had hoped, leading to disappointment in the market.\nAdditionally, BridgeBio presented initial outcomes from the ATTRibute-CM open-label extension study of acoramidis in ATTR-CM (transthyretin amyloid cardiomyopathy) at the American Heart Association Scientific Sessions. The data, while encouraging, failed to significantly boost investor confidence in the therapy's potential.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}